How do you treat patients with early-stage ER+/Her2- breast cancer who recur years later after definitive therapy and hormonal therapy?

There's a lot of nuances to this question. What's the disease burden? Is there considerable visceral disease? What is the performance status of the patient? And finally, patient preference? If there is considerable visceral disease, I do consider single agent chemotherapy for a few cycles, and very ...